{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(10)"],"submitter":["Sato K"],"pubmed_abstract":["<h4>Importance</h4>Excess salt intake is a major modifiable risk factor for hypertension and cardiovascular disease. Personalized interventions using genetic information and digital tools, such as smartphone applications, may enhance sodium reduction, but evidence remains limited.<h4>Objective</h4>To evaluate the effectiveness of a sodium reduction program incorporating a genetic profile and an artificial intelligence (AI)-based mobile app among adults with elevated blood pressure and a sodium-sensitive genotype.<h4>Design, setting, and participants</h4>A 3-arm randomized clinical trial, conducted at a Japanese electronics company from September 17 to December 16, 2024, included employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype.<h4>Inter"],"journal":["JAMA network open"],"pagination":["e2537540"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12531883"],"repository":["biostudies-literature"],"pubmed_title":["Sodium Reduction Program Incorporating Genetic Profile and an AI-Based App: A Randomized Clinical Trial."],"pmcid":["PMC12531883"],"pubmed_authors":["Yanagisawa T","Yagi M","Yamaguchi T","Mizuno S","Node K","Akiyama N","Kondo N","Sato K","Inoue K","Furukawa TA","Ebisawa M"],"additional_accession":[]},"is_claimable":false,"name":"Sodium Reduction Program Incorporating Genetic Profile and an AI-Based App: A Randomized Clinical Trial.","description":"<h4>Importance</h4>Excess salt intake is a major modifiable risk factor for hypertension and cardiovascular disease. Personalized interventions using genetic information and digital tools, such as smartphone applications, may enhance sodium reduction, but evidence remains limited.<h4>Objective</h4>To evaluate the effectiveness of a sodium reduction program incorporating a genetic profile and an artificial intelligence (AI)-based mobile app among adults with elevated blood pressure and a sodium-sensitive genotype.<h4>Design, setting, and participants</h4>A 3-arm randomized clinical trial, conducted at a Japanese electronics company from September 17 to December 16, 2024, included employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype.<h4>Inter","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-07-15T12:08:54.686Z","creation":"2026-07-04T03:11:54.264Z"},"accession":"S-EPMC12531883","cross_references":{"pubmed":["41100086"],"doi":["10.1001/jamanetworkopen.2025.37540"]}}